Dogwood Therapeutics, Inc. (DWTX)
| Market Cap | 45.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.51M |
| Shares Out | 33.40M |
| EPS (ttm) | -7.13 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 76,123 |
| Open | 1.360 |
| Previous Close | 1.340 |
| Day's Range | 1.340 - 1.440 |
| 52-Week Range | 1.282 - 9.500 |
| Beta | 2.07 |
| Analysts | Strong Buy |
| Price Target | 12.00 (+788.89%) |
| Earnings Date | May 8, 2026 |
About DWTX
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended t... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for DWTX stock is "Strong Buy" and the 12-month stock price target is $12.0.
News
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royal...
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected...
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, ...
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeut...
Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development
ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a company that focuses on developing new non-opioid medicines to treat pain and neur...
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 -
Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045
- New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron®- - New Synthetic Process to be Used for Phase 3 Development Prov...
Dogwood Therapeutics Transcript: EGM 2025
Five proposals, including stock conversions and an equity plan, were presented and approved by majority vote. No questions were raised, and all voting procedures complied with legal and NASDAQ requirements. Final results will be filed with the SEC.
Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
- Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well tolerated ATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dog...
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release -
Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
ATLANTA, GA / ACCESS Newswire / October 30, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development‐stage biotechnology company developing new medicines to treat pain and neurop...
Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025
ATLANTA, GA / ACCESS Newswire / October 14, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neurop...
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit
ATLANTA, GEORGIA / ACCESS Newswire / October 7, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain, today...
Dogwood Therapeutics Transcript: Study Update
Halneuron’s phase II-B trial for chemotherapy-induced neuropathy pain is progressing well, with an interim analysis set for Q4 and final data expected mid-2026. SP16, a novel LRP1 agonist, enters a fully NCI-funded phase I-B trial next year, offering complementary mechanisms and market expansion opportunities.
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients
-A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer Institute, with projected patient enrollment beginning in the first half ...
Dogwood Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The company is advancing Halneuron, a selective Nav1.7 inhibitor, through a phase II-B trial for chemotherapy-induced neuropathic pain, with interim results expected by year-end and final data in mid-2026. A synthetic formulation aims to reset the patent clock, and the company maintains a strong financial position with support from major shareholders.
Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
ATLANTA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-rel...
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
- Enrollment to-date of 52 patients in the ongoing Halneuron® Phase 2b Trial - - Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track for Q4 2...
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
- Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 -
Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development‐stage biotechnology company developing new medicines to treat pain and fatigue-relat...
Dogwood Therapeutics Transcript: Sidoti's Small-Cap Virtual Conference
Halneuron, a non-opioid pain therapy, shows strong efficacy and safety in cancer-related pain, with long-lasting relief and no addiction risk. Key milestones include new IP filings, interim phase II-B data in Q4 2025, and final results in mid-2026.
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
ATLANTA, June 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biotechnology company developing new medicines to treat pain and...
Dogwood Therapeutics Announces First Quarter 2025 Financial Results
- Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Study - - Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b study int...
Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
Alpharetta, Georgia--(Newsfile Corp. - May 1, 2025) - Dogwood Therapeutics, Inc. (NASDAQ: DWTX), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May...
Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance
ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain a...